Gene therapy research is expensive. Biotechs invest millions of dollars in early research to develop therapies for conditions that might be rare. But when funds are limited and the market potential is dim, such programs are often abandoned by companies, leaving patients and investigators in a bind.
In this month’s cover story, we take a look at one such case where a hospital network is trying to save access to a gene therapy program for a rare disorder called adenosine deaminase deficient-severe combined immunodeficiency (ADA-SCID).
Go deeper with GlobalData
Also in this issue, an interview explores how generative artificial intelligence (genAI) is influencing drug discovery and the market’s reaction to drugs developed using AI. We also explore the challenges with clinical trials gathering more data than ever before and the burden this may place on patients and investigators. All this, along with the latest news and deals in the pharmaceutical landscape.
Read the latest issue of Pharma Technology Focus for all this and insights, and analysis from the pharmaceutical industry
You can also subscribe here to receive email notifications when a new issue is available.
In this issue, we also have a full supplement dedicated to cybersecurity. We will look at the evolving threat landscape, the impact of generative AI, the latest technological advances in cybersecurity and everything business leaders need to know to protect their organisations from cyber threats.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataYou can read the supplement in our latest issue. For more information about sponsorship opportunities and our Thematic Take supplements, please click here.
